| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04129528 | Study of Safety and Efficacy of CFZ533 in Type 1 Diabetes Pediatric and Young Adult Subjects | PHASE2 | COMPLETED | 44 | — | — | Nov 8, 2019 | Jun 4, 2024 | Apr 8, 2025 | 12 | Belgium, Germany +4 |
Number of participants with treatment emergent AEs (any AE regardless of seriousness), AEs led to study treatment discontinuation, and SAEs. On-treatment period is defined as from date of first administration of study treatment to 98 days after date of last administration of study treatment (including start and stop date).
The mixed meal tolerance test (MMTT) has appropriate sensitivity to detect residual insulin secretion and beta cell function. In the MMTT, following an 8-10 hour overnight fast, a weight-based liquid meal provided as 6 mL/kg (maximum 360 mL) of mixed meal, ingested over 5 min with timed blood samples for glucose and C peptide determination obtained 10 min prior to ingestion (t = -10), at baseline (t = 0), and at 15, 30, 60, 90, and 120 min after consumption of the liquid meal. The time collections for post load samples are based on the start time of the mixed meal. Stimulated C-peptide AUC by the standard MMTT, normalized by the duration of measurements, was analyzed with a mixed model repeated measures analysis.
| Arm | Type | Description |
|---|---|---|
| CFZ533 | ACTIVE_COMPARATOR | Randomized in a 2:1 ratio: 2 Active / 1 Placebo |
| Placebo | PLACEBO_COMPARATOR | Similar in appearance to active study drug |
| Name | Type | Description |
|---|---|---|
| CFZ533 | DRUG | First dose is administered via intravenous infusion, subsequent doses are administered subcutaneously. |
| Placebo | OTHER | Placebo for active drug |
Inclusion Criteria: 1. Written informed consent, and if needed assent from the child on the trial, must be obtained before any assessment is performed. 2. Males and females aged between 12 and 21 years (inclusive, and enrolled in stages) at screening. 3. Body weight range from 30 to 125 kg (inclusi...